Please upgrade your browser.
Daniel J. George, MD, of Duke Cancer Institute, gives an overview of what is on the horizon in renal cell cancer (RCC) research. Topics discussed include emerging clinical trials, how to move forward with predictive biomarkers, clinical outcomes for RCC trials, and unmet needs in advanced RCC that Dr. George describes as being “imminently attainable.”
Standard single-agent treatment options offer meager prospects for metastatic sarcomatoid renal cell carcinoma (RCC) and poor-risk RCC, both of which demonstrate aggressive tumor biology and rapid clinical disease progression. However, results of a single-arm, open-label, phase II trial suggest that combining select treatment options may deliver the necessary punch to keep these aggressive forms of RCC in check (Abstract 408).
Interfering with two different stages of angiogenesis concurrently proves promising in clear cell renal cell carcinoma (RCC) based on early clinical results from the DART trial. In this phase Ib study of combined treatment with axitinib and dalantercept, objective responses have been observed in 25% of patients, along with a preliminary median progression-free survival duration of 8.3 months (Abstract 407).
Body mass index (BMI) predicts survival and overall response (ORR) rates in patients with metastatic clear cell renal cell carcinoma, according to authors of an external validation data analysis (Abstract 405) presented during the 2015 Genitourinary Cancers Symposium.
Use the hashtag #kidneycancer and @kidneycancer when you Tweet during March, Kidney Cancer Awareness Month. Help increase awareness and the need for a cure!
Despite that several VEGF, VEGF receptor (VEGFR), and mTOR inhibitors are approved for metastatic renal cell carcinoma (mRCC), the benefit patients receive from these classes of agents has reached a plateau.
Kidney Cancer Association educates patients about the value of clinical trials.
Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent® (sunitinib) or Nexavar® (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence...
he purpose of this study was to examine the prevalence of posttraumatic stress symptoms (PTSS) in patients with renal cell carcinoma (RCC), the associations and co–occurrence between PTSS, depressive, and other cancer–related symptoms...
At the Thirteenth International Kidney Cancer Symposium, Dr Toni Choueiri (Dana-Farber Cancer Institute and Harvard Medical School, MA) discusses the new AstraZeneca-sponsored Phase 2 clinical trial on the c-Met inhibitor, volitinib, in patients with papillary renal cell carcinoma (pRCC).
|NeonCRM by Neon One|